About

Mechanical circulatory support has emerged as an important therapy for advanced heart failure. These devices significantly improve survival and quality of life and should be considered in every patient with end-stage heart failure with reduced ejection fraction who has no other life-limiting diseases.

Devices, such as implantable cardioverter-defibrillators (ICDs), and novel pacing technologies, including cardiac resynchronisation therapy (CRT), have helped to complement goal-directed medical therapy and positively impact prognosis in these patients, as demonstrated in multiple high-quality clinical trials.

Articles

Ventricular Assist Devices: Challenges of the One-device Era

Published:

18 November 2022

Citation:

Cardiac Failure Review 2022;8:e33.

TAVR and SAVR Outcomes in LVAD Patients with AI

Published:

07 October 2022

Citation:

Cardiac Failure Review 2022;8:e30.

ATLAS: What do the Superiority Results Mean for S-ICD Therapy?

Published:

05 September 2022

Citation:

Arrhythmia & Electrophysiology Review 2022;11(Suppl 1):1–7.

ICU Management of Cardiogenic Shock

Published:

25 July 2022

Citation:

US Cardiology Review 2022;16:e20.